Daysi Zulema Diaz-Obregón
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Daysi Zulema Diaz-Obregón has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Alexis Germán Murillo Carrasco
Center for Translational Research in Oncology (LIM24), Instituto do Cancer do Estado de Sao Paulo (ICESP), Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), São Paulo 01246-000, Brazil, São Paulo, Brazil
5 shared publications - Joel de León Delgado
Center of Virology Research, Faculty of Human Medicine, University of San Martín de Porres, Lima 15011, Peru
3 shared publications - Ana Cecilia Granda Alacote
ONG Innovation and Science for the Care and Support of Society–INNOVACARE, Lima 15036, Peru
2 shared publications - Cesar Liendo Liendo
Nephrology Center-CENESA, Lima 15072, Peru
2 shared publications - Gabriela Goyoneche Linares
ONG Innovation and Science for the Care and Support of Society–INNOVACARE, Lima 15036, Peru
2 shared publications - Katherine Susan Rufasto Goche
Postgraduate School, Universidad Nacional Federico Villarreal, Lima 15001, Peru
2 shared publications
Latest Publications
- Open Access
- 3 June 2026
- Published by MDPI AG in Medical Sciences
- Vol. 14 (2) , 287
Effectiveness of Peritoneal Lavage in Reducing Postoperative Pain in Elective Laparoscopic Cholecystectomy: A Prospective Cohort Study
Introduction: Postoperative pain in laparoscopic cholecystectomy is not well studied. Peritoneal lavage is performed in cases of acute or complicated cholecystitis, whereas it is uncommon in cases considered clean surgeries; paradoxically, this latter group reports more pain. Objective: To evaluate the association between peritoneal lavage and postoperative pain levels in patients undergoing laparoscopic cholecystectomy. Methods: Prospective cohort study on 110 patients with gallbladder pathology scheduled for elective laparoscopic cholecystectomy. Groups: with peritoneal lavage (n1 = 55) and without peritoneal lavage (n2 = 55). Pain was evaluated at 6, 12, and 24 h using the visual analog scale (VAS). Numeric variables were described as means or medians. Categorical variables were described as absolute frequencies and percentages. The association between peritoneal lavage and postoperative pain levels was analyzed using Linear Quantile Mixed Models (LQMMs) with the ‘lqmm’ package in R. Results: Pain assessment shows that the median pain scale scores were significantly lower at 6, 12, and 24 postoperative hours (p < 0.001) in patients who received peritoneal lavage. The adjusted median differences ranged from −1.6 to −1.7 points on the VAS across all evaluated time points, indicating consistently lower postoperative pain scores in the lavage group. Conclusions: Peritoneal lavage with saline solution during laparoscopic cholecystectomy was associated with lower postoperative pain scores during the first 24 postoperative hours.
- 3 June 2026
- Published by MDPI AG in Medical Sciences
- Vol. 14 (2) , 287
Open AccessEffectiveness of Peritoneal Lavage in Reducing Postoperative Pain in Elective Laparoscopic Cholecystectomy: A Prospective Cohort Study
Introduction: Postoperative pain in laparoscopic cholecystectomy is not well studied. Peritoneal lavage is performed in cases of acute or complicated cholecystitis, whereas it is uncommon in cases considered clean surgeries; paradoxically, this latter group reports more pain. Objective: To evaluate the association between peritoneal lavage and postoperative pain levels in patients undergoing laparoscopic cholecystectomy. Methods: Prospective cohort study on 110 patients with gallbladder pathology scheduled for elective laparoscopic cholecystectomy. Groups: with peritoneal lavage (n1 = 55) and without peritoneal lavage (n2 = 55). Pain was evaluated at 6, 12, and 24 h using the visual analog scale (VAS). Numeric variables were described as means or medians. Categorical variables were described as absolute frequencies and percentages. The association between peritoneal lavage and postoperative pain levels was analyzed using Linear Quantile Mixed Models (LQMMs) with the ‘lqmm’ package in R. Results: Pain assessment shows that the median pain scale scores were significantly lower at 6, 12, and 24 postoperative hours (p < 0.001) in patients who received peritoneal lavage. The adjusted median differences ranged from −1.6 to −1.7 points on the VAS across all evaluated time points, indicating consistently lower postoperative pain scores in the lavage group. Conclusions: Peritoneal lavage with saline solution during laparoscopic cholecystectomy was associated with lower postoperative pain scores during the first 24 postoperative hours.
- Open Access
Integrated Functional and Histopathological Modulation of Chronic Thioacetamide-Induced Liver Fibrosis by Mesenchymal Stem Cell Therapy in a Preclinical Model
Background: Chronic liver fibrosis is a progressive pathological condition characterized by excessive extracellular matrix deposition and architectural remodeling, which may ultimately lead to cirrhosis and liver failure. Although mesenchymal stem cells (MSCs) exhibit antifibrotic and immunomodulatory properties, their therapeutic effects in established chronic liver fibrosis remain incompletely defined. This study aimed to evaluate the biochemical, hematological, and histopathological effects of MSC therapy in a chronic thioacetamide-induced liver fibrosis model. Methods: A controlled preclinical experimental study was conducted using rats with liver fibrosis induced by intraperitoneal thioacetamide administration for 24 weeks. Animals were allocated into three groups: control, untreated fibrosis, and fibrosis treated with MSCs derived from human umbilical cord tissue after fibrosis establishment. Serum biochemical markers, hematological parameters, and liver histopathology were assessed. Fibrosis severity was evaluated using hematoxylin–eosin and Masson’s trichrome staining and graded according to the METAVIR scoring system. Results: Thioacetamide exposure induced chronic liver injury characterized by marked elevations in serum transaminases, reduced albumin and total protein levels, hematological alterations, and early-to-intermediate fibrosis stages (METAVIR F1–F2). MSC-treated animals exhibited approximately 40–45% reductions in transaminase levels, partial recovery of hepatic synthetic function, and attenuation of hematological alterations. Histopathological analysis demonstrated a reduction in fibrotic burden and limitation of fibrogenic progression within METAVIR F1–F2 stages. Conclusions: MSC therapy partially mitigates biochemical, hematological, and histopathological alterations associated with chronic thioacetamide-induced liver fibrosis, supporting its potential as a modulatory strategy to attenuate fibrogenic progression and stabilize liver function rather than as a curative intervention.
Open AccessIntegrated Functional and Histopathological Modulation of Chronic Thioacetamide-Induced Liver Fibrosis by Mesenchymal Stem Cell Therapy in a Preclinical Model
Background: Chronic liver fibrosis is a progressive pathological condition characterized by excessive extracellular matrix deposition and architectural remodeling, which may ultimately lead to cirrhosis and liver failure. Although mesenchymal stem cells (MSCs) exhibit antifibrotic and immunomodulatory properties, their therapeutic effects in established chronic liver fibrosis remain incompletely defined. This study aimed to evaluate the biochemical, hematological, and histopathological effects of MSC therapy in a chronic thioacetamide-induced liver fibrosis model. Methods: A controlled preclinical experimental study was conducted using rats with liver fibrosis induced by intraperitoneal thioacetamide administration for 24 weeks. Animals were allocated into three groups: control, untreated fibrosis, and fibrosis treated with MSCs derived from human umbilical cord tissue after fibrosis establishment. Serum biochemical markers, hematological parameters, and liver histopathology were assessed. Fibrosis severity was evaluated using hematoxylin–eosin and Masson’s trichrome staining and graded according to the METAVIR scoring system. Results: Thioacetamide exposure induced chronic liver injury characterized by marked elevations in serum transaminases, reduced albumin and total protein levels, hematological alterations, and early-to-intermediate fibrosis stages (METAVIR F1–F2). MSC-treated animals exhibited approximately 40–45% reductions in transaminase levels, partial recovery of hepatic synthetic function, and attenuation of hematological alterations. Histopathological analysis demonstrated a reduction in fibrotic burden and limitation of fibrogenic progression within METAVIR F1–F2 stages. Conclusions: MSC therapy partially mitigates biochemical, hematological, and histopathological alterations associated with chronic thioacetamide-induced liver fibrosis, supporting its potential as a modulatory strategy to attenuate fibrogenic progression and stabilize liver function rather than as a curative intervention.
- Open Access
Leukocyte Dysregulation and Biochemical Alterations in End-Stage Kidney Disease Patients Under Hemodialysis
Background: Patients with chronic kidney disease (CKD) exhibit changes in leukocyte dynamics, leading to altered hematological and biochemical parameters and deteriorating kidney function. In this study, we aim to investigate the correlation between leukocyte subpopulations and hematological and biochemical parameters in patients with end-stage CKD undergoing hemodialysis. Methods: This descriptive, analytical, cross-sectional study included 20 end-stage CKD patients on hemodialysis. Leukocyte subpopulations, including classical monocytes (CD14++/CD16−), intermediate monocytes (CD14++/CD16+), non-classical monocytes (CD14+/CD16++), CD4 T lymphocytes (CD3+/CD4+), CD8 T lymphocytes (CD3+/CD8+), B lymphocytes (CD3−/CD19+), NK cells (CD56+/CD16+), and iNKT cells (CD3+/CD56+), were analyzed using flow cytometry. Results: Patients with end-stage CKD on hemodialysis have decreased classical monocytes and increased non-classical monocytes frequency. A positive correlation was observed between non-classical monocytes and total lymphocytes (Rho-Spearman: R = 0.495, p = 0.027) as well as B lymphocytes (R = 0.567, p < 0.05). We discerned the immunological characteristics of diabetic kidney disease (DKD) and CKD due to other causes in this balanced cohort: B lymphocytes negatively correlate with alkaline phosphatase (R = −0.764, p < 0.05), parathyroid hormone (R = −0.929, p < 0.05), and ferritin (R = −0.893, p < 0.05). Additionally, in DKD, non-classical monocytes positively correlate with eosinophils (R = +0.691; p = 0.019) and classic monocytes with neutrophils (R = +0.627, p = 0.039). Meanwhile, a correlation between either total T lymphocytes or helper T lymphocytes and serum albumin was detected on patients with nephropathy due to other causes. Conclusions: CKD alters classical and non-classical monocyte frequency, whilst T and B lymphocyte frequency positively correlates to the proinflammatory non-classical monocytes. In DKD patients, the uremic environment increases classic monocytes, CD16+ inflammatory monocytes, neutrophils, eosinophils, and B lymphocytes. The described leukocyte dynamic correlates with alkaline phosphatase, parathyroid hormone, iron, and serum albumin serological concentration.
Open AccessLeukocyte Dysregulation and Biochemical Alterations in End-Stage Kidney Disease Patients Under Hemodialysis
Background: Patients with chronic kidney disease (CKD) exhibit changes in leukocyte dynamics, leading to altered hematological and biochemical parameters and deteriorating kidney function. In this study, we aim to investigate the correlation between leukocyte subpopulations and hematological and biochemical parameters in patients with end-stage CKD undergoing hemodialysis. Methods: This descriptive, analytical, cross-sectional study included 20 end-stage CKD patients on hemodialysis. Leukocyte subpopulations, including classical monocytes (CD14++/CD16−), intermediate monocytes (CD14++/CD16+), non-classical monocytes (CD14+/CD16++), CD4 T lymphocytes (CD3+/CD4+), CD8 T lymphocytes (CD3+/CD8+), B lymphocytes (CD3−/CD19+), NK cells (CD56+/CD16+), and iNKT cells (CD3+/CD56+), were analyzed using flow cytometry. Results: Patients with end-stage CKD on hemodialysis have decreased classical monocytes and increased non-classical monocytes frequency. A positive correlation was observed between non-classical monocytes and total lymphocytes (Rho-Spearman: R = 0.495, p = 0.027) as well as B lymphocytes (R = 0.567, p < 0.05). We discerned the immunological characteristics of diabetic kidney disease (DKD) and CKD due to other causes in this balanced cohort: B lymphocytes negatively correlate with alkaline phosphatase (R = −0.764, p < 0.05), parathyroid hormone (R = −0.929, p < 0.05), and ferritin (R = −0.893, p < 0.05). Additionally, in DKD, non-classical monocytes positively correlate with eosinophils (R = +0.691; p = 0.019) and classic monocytes with neutrophils (R = +0.627, p = 0.039). Meanwhile, a correlation between either total T lymphocytes or helper T lymphocytes and serum albumin was detected on patients with nephropathy due to other causes. Conclusions: CKD alters classical and non-classical monocyte frequency, whilst T and B lymphocyte frequency positively correlates to the proinflammatory non-classical monocytes. In DKD patients, the uremic environment increases classic monocytes, CD16+ inflammatory monocytes, neutrophils, eosinophils, and B lymphocytes. The described leukocyte dynamic correlates with alkaline phosphatase, parathyroid hormone, iron, and serum albumin serological concentration.
- Open Access
- 27 February 2025
- Published by MDPI AG in Healthcare
- Vol. 13 (5) , 514
Development of a Health Research Portfolio Based on Priority Topics for Peruvian Social Health Insurance (ESSALUD) in 2023–2025: A Collaborative Approach to Addressing Institutional and Public Health Challenges
Background/Objectives: Addressing health research priorities in public institutions is crucial for efficient resource allocation and policy impact. This study aims to describe the development of Peru’s Social Health Insurance (ESSALUD) 2023–2025 research portfolio, which aligns with institutional priorities and focuses on improving decision-making for population health. Methods: The Health Research Directorate (DIS) of ESSALUD led a structured three-phase process, engaging multidisciplinary teams and utilizing a group model-building approach to generate research ideas. Twelve working groups were established, corresponding to ESSALUD’s prioritized health topics, to identify key institutional challenges and propose research ideas. Results: A total of 338 research ideas were generated from 217 identified problems. These ideas were classified using the UK Health Research Classification System (HRCS) and scored based on nine dimensions to prioritize execution. Research ideas primarily focused on health services (57.7%) and disease management (16.9%). High-priority topics included cancer, mental health, malnutrition, and antimicrobial resistance. As a result of this implementation, ESSALUD resources were positively concentrated in the HRCS research activities ‘Health and social care services research’ (51.85%) and ‘Etiology’ (44.44%) for the period 2023–2025. Conclusions: The development of ESSALUD’s research portfolio identified key areas such as health services, health economics, and prevention, essential for evidence-based decisions and sustainability. Multidisciplinary participation ensured solutions aligned with real needs, promoting equity and continuous improvement in Peru’s health system.
- 27 February 2025
- Published by MDPI AG in Healthcare
- Vol. 13 (5) , 514
Open AccessDevelopment of a Health Research Portfolio Based on Priority Topics for Peruvian Social Health Insurance (ESSALUD) in 2023–2025: A Collaborative Approach to Addressing Institutional and Public Health Challenges
Background/Objectives: Addressing health research priorities in public institutions is crucial for efficient resource allocation and policy impact. This study aims to describe the development of Peru’s Social Health Insurance (ESSALUD) 2023–2025 research portfolio, which aligns with institutional priorities and focuses on improving decision-making for population health. Methods: The Health Research Directorate (DIS) of ESSALUD led a structured three-phase process, engaging multidisciplinary teams and utilizing a group model-building approach to generate research ideas. Twelve working groups were established, corresponding to ESSALUD’s prioritized health topics, to identify key institutional challenges and propose research ideas. Results: A total of 338 research ideas were generated from 217 identified problems. These ideas were classified using the UK Health Research Classification System (HRCS) and scored based on nine dimensions to prioritize execution. Research ideas primarily focused on health services (57.7%) and disease management (16.9%). High-priority topics included cancer, mental health, malnutrition, and antimicrobial resistance. As a result of this implementation, ESSALUD resources were positively concentrated in the HRCS research activities ‘Health and social care services research’ (51.85%) and ‘Etiology’ (44.44%) for the period 2023–2025. Conclusions: The development of ESSALUD’s research portfolio identified key areas such as health services, health economics, and prevention, essential for evidence-based decisions and sustainability. Multidisciplinary participation ensured solutions aligned with real needs, promoting equity and continuous improvement in Peru’s health system.
- Open Access
- 24 December 2024
- Published by MDPI AG in Biomedicines
- Vol. 13 (1) , 3
T-Cell Subpopulations and Differentiation Bias in Diabetic and Non-Diabetic Patients with Chronic Kidney Disease
Background: Chronic kidney disease (CKD) patients often experience dysregulated inflammation, particularly when compounded by comorbidities such as type 2 diabetes (T2D). Objective: The aim of this study was to determine whether T2D influences the profile of memory T lymphocytes, regulatory T cells (Tregs), and the gene expression of transcription factors such as T-bet (Tbx21), GATA3, RORyT (RORC), and FOXP3 in CKD patients. Methods: Twenty-two CKD patients undergoing hemodialysis were selected for the study. Flow cytometry was used to identify naïve T cells, Tregs (CD4+CD25+CD127-), central memory T lymphocytes (CCR7+CD45RA-), effector memory T lymphocytes (CCR7-CD45RA-), and TEMRA cells (CCR7-CD45RA+). The expression of helper T cell differentiation regulatory genes was assessed using real-time RT-PCR. Results: Both helper and cytotoxic effector memory T cell populations were found to be higher than naïve lymphocytes in CKD patients, regardless of T2D status. However, Tregs were significantly more frequent in diabetic CKD patients (5.1 ± 2.6%) compared to non-diabetic patients (2.8 ± 3.1%). In terms of transcription factor expression, a significant correlation was observed between T-bet and FOXP3 in diabetic patients, and between RORyT and FOXP3 in non-diabetic patients. Conclusions: While T2D does not notably alter the distribution of memory T cells in CKD patients, it significantly impacts the frequency of Tregs and their correlation with pro-inflammatory transcription factors like T-bet (Tbx21) and RORyT.
- 24 December 2024
- Published by MDPI AG in Biomedicines
- Vol. 13 (1) , 3
Open AccessT-Cell Subpopulations and Differentiation Bias in Diabetic and Non-Diabetic Patients with Chronic Kidney Disease
Background: Chronic kidney disease (CKD) patients often experience dysregulated inflammation, particularly when compounded by comorbidities such as type 2 diabetes (T2D). Objective: The aim of this study was to determine whether T2D influences the profile of memory T lymphocytes, regulatory T cells (Tregs), and the gene expression of transcription factors such as T-bet (Tbx21), GATA3, RORyT (RORC), and FOXP3 in CKD patients. Methods: Twenty-two CKD patients undergoing hemodialysis were selected for the study. Flow cytometry was used to identify naïve T cells, Tregs (CD4+CD25+CD127-), central memory T lymphocytes (CCR7+CD45RA-), effector memory T lymphocytes (CCR7-CD45RA-), and TEMRA cells (CCR7-CD45RA+). The expression of helper T cell differentiation regulatory genes was assessed using real-time RT-PCR. Results: Both helper and cytotoxic effector memory T cell populations were found to be higher than naïve lymphocytes in CKD patients, regardless of T2D status. However, Tregs were significantly more frequent in diabetic CKD patients (5.1 ± 2.6%) compared to non-diabetic patients (2.8 ± 3.1%). In terms of transcription factor expression, a significant correlation was observed between T-bet and FOXP3 in diabetic patients, and between RORyT and FOXP3 in non-diabetic patients. Conclusions: While T2D does not notably alter the distribution of memory T cells in CKD patients, it significantly impacts the frequency of Tregs and their correlation with pro-inflammatory transcription factors like T-bet (Tbx21) and RORyT.